Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
Healthcare
$7.22 +2.21%
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
52W Low $3.03High $7.90
Volume 0.45M
Average 0.26M
Income Statement
Follow revenue through to earnings.
Revenue
$228.37M
FY 2025 · Annual
-0.9% YoYOperating Income
$37.30M
FY 2025 · Annual
+20.5% YoYNet Income
$31.11M
FY 2025 · Annual
+2.8% YoYIncome Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M |
| Cost of Revenue | 63.7M | 55.09M | 62.68M | 64.4M | 58.16M |
| Gross Profit | 189.45M | 172.94M | 172.96M | 166.06M | 170.21M |
| Gross Margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Research & Development | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M |
| Selling, General & Admin | 116.29M | 89.98M | 89.31M | 80.16M | 71.21M |
| Operating Expenses | 188.16M | 149.22M | 140.32M | 135.1M | 132.92M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| EBITDA | (4.69M) | 21.89M | 47.52M | 48.08M | 53.34M |
| EBITDA Margin | -1.9% | 9.6% | 20.2% | 20.9% | 23.4% |
| Operating Income | 1.29M | 23.72M | 32.64M | 30.97M | 37.3M |
| Operating Margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Interest Income | 160K | 813K | 2.61M | 4.72M | 4.08M |
| Interest Expense | 12.81M | 11.59M | 13.33M | 12.45M | 6.62M |
| Other Income / Expenses | (30.09M) | (23.26M) | (9.97M) | (6.87M) | (1.52M) |
| Income Before Tax | (28.8M) | 457K | 22.67M | 24.1M | 35.78M |
| Pre-Tax Margin | -11.4% | 0.2% | 9.6% | 10.5% | 15.7% |
| Income Tax Expense | 324K | 455K | 1.08M | (6.18M) | 4.67M |
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Net Margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (Basic) | (0.72) | 0.02 | 0.46 | 0.62 | 0.62 |
| EPS (Diluted) | (0.72) | 0.02 | 0.45 | 0.62 | 0.61 |
| 40.64M | 44.67M | 47.13M | 48.65M | 50.01M | |
| 40.64M | 44.93M | 47.55M | 49.1M | 50.65M |
PBYI Earnings Waterfall · TTM
NASDAQ:PBYI · Revenue to Net Income
Key Ratios
EPS$0.48
Gross Margin75.1%
Net Margin9.2%
P/E Ratio-0.3
P/S Ratio4.8
Analysis
$227.2M of revenue converted into $24.4M of net income for the selected period. Gross margin is 75.1% and net margin is 9.2%, showing how much revenue survives after costs and taxes. EPS is $0.48, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 16, 2026 |
How much revenue does PBYI generate?
Puma Biotechnology, Inc. (PBYI) reported $228.37M of revenue in fiscal 2025.
Is PBYI profitable?
Puma Biotechnology, Inc. (PBYI) reported $31.11M of net income, with a net margin of 13.6%.
Continue the stock analysis
Jump to another research area for this company.